|The genetic landscape of high-risk neuroblastoma|
TJ Pugh, O Morozova, EF Attiyeh, S Asgharzadeh, JS Wei, D Auclair, ...
Nature genetics 45 (3), 279-284, 2013
|Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations|
TF Eleveld, DA Oldridge, V Bernard, J Koster, LC Daage, SJ Diskin, ...
Nature genetics 47 (8), 864-871, 2015
|Common variations in BARD1 influence susceptibility to high-risk neuroblastoma|
M Capasso, M Devoto, C Hou, S Asgharzadeh, JT Glessner, EF Attiyeh, ...
Nature genetics 41 (6), 718-723, 2009
|Chromosome 6p22 locus associated with clinically aggressive neuroblastoma|
JM Maris, YP Mosse, JP Bradfield, C Hou, S Monni, RH Scott, ...
New England Journal of Medicine 358 (24), 2585-2593, 2008
|Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages|
L Song, S Asgharzadeh, J Salo, K Engell, H Wu, R Sposto, T Ara, ...
The Journal of clinical investigation 119 (6), 1524-1536, 2009
|Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification|
S Asgharzadeh, R Pique-Regi, R Sposto, H Wang, Y Yang, H Shimada, ...
Journal of the National Cancer Institute 98 (17), 1193-1203, 2006
|Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy|
KB Challagundla, PM Wise, P Neviani, H Chava, M Murtadha, T Xu, ...
JNCI: Journal of the National Cancer Institute 107 (7), 2015
|Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2|
LS Metelitsa, HW Wu, H Wang, Y Yang, Z Warsi, S Asgharzadeh, ...
The Journal of experimental medicine 199 (9), 1213-1221, 2004
|Comparison of RNA-seq and microarray-based models for clinical endpoint prediction|
W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang, D Thierry-Mieg, ...
Genome biology 16 (1), 1-12, 2015
|NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome|
M Hölzel, S Huang, J Koster, I Øra, A Lakeman, H Caron, W Nijkamp, ...
Cell 142 (2), 218-229, 2010
|Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma|
S Asgharzadeh, JA Salo, L Ji, A Oberthuer, M Fischer, F Berthold, ...
Journal of Clinical Oncology 30 (28), 3525, 2012
|Sparse representation and Bayesian detection of genome copy number alterations from microarray data|
R Pique-Regi, J Monso-Varona, A Ortega, RC Seeger, TJ Triche, ...
Bioinformatics 24 (3), 309-318, 2008
|ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome|
S Huang, J Laoukili, MT Epping, J Koster, M Hölzel, BA Westerman, ...
Cancer cell 15 (4), 328-340, 2009
|Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous …|
SL Gardner, S Asgharzadeh, A Green, B Horn, G McCowage, J Finlay
Pediatric blood & cancer 51 (2), 235-240, 2008
|Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed …|
J Fangusaro, J Finlay, R Sposto, L Ji, M Saly, S Zacharoulis, ...
Pediatric blood & cancer 50 (2), 312-318, 2008
|Prognostic impact of gene expression–based classification for neuroblastoma|
A Oberthuer, B Hero, F Berthold, D Juraeva, A Faldum, Y Kahlert, ...
Journal of Clinical Oncology 28 (21), 3506-3515, 2010
|CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus|
MR Russell, A Penikis, DA Oldridge, JR Alvarez-Dominguez, L McDaniel, ...
Cancer research 75 (15), 3155-3166, 2015
|Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue|
S Zacharoulis, A Levy, SN Chi, S Gardner, M Rosenblum, DC Miller, ...
Pediatric blood & cancer 49 (1), 34-40, 2007
|IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity|
D Liu, L Song, J Wei, AN Courtney, X Gao, E Marinova, L Guo, A Heczey, ...
The Journal of clinical investigation 122 (6), 2221-2233, 2012
|Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity|
KR Bosse, SJ Diskin, KA Cole, AC Wood, RW Schnepp, G Norris, ...
Cancer research 72 (8), 2068-2078, 2012